SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

AMI Patients

XIENCE™ Stent in AMI Patients

Low long-term event rates are critical for acute myocardial infarction (AMI) patients, and XIENCE™ Stent findings show excellent early outcomes in AMI patients.2 Contributing to these results are several features of XIENCE™ Stent:

  • Innovative stent design
  • Anti-thrombotic fluoropolymer3
  • Market-leading everolimus4


XIENCE™ Stent AMI Safety Data Apparent at 2 Weeks

The XIENCE™ Stent fluoropolymer exhibits improved anti-inflammatory characteristics compared to other drug-eluting stents (DES).3 This may be a key factor why the XIENCE™ Stent has such impressive safety data within 2 weeks post percutaneous coronary intervention (PCI) among AMI patients. Data show that—compared to immediately post intervention—XIENCE™ Stent reveals significant progression at 2 weeks post PCI2 in terms of:

  • Better strut coverage (p<0.01)
  • Less thrombus (p=0.03)
  • Larger average lumen area (p=0.048)

 

By 2 weeks post PCI XIENCE data shows ~80% strut coverage and significantly less thrombus than immediately post PCI.

Strut Coverage and Thrombosis2

In acute myocardial infarction patients, XIENCE Stent has a significantly larger lumen area at 2 weeks vs post implant.

Post PCI

In acute myocardial infarction patients, XIENCE Stent has a significantly larger lumen area at 2 weeks vs post implant.

2 Weeks Post PCI

Less Thrombosis, Larger Lumen Area at 2 Weeks2

XIENCE™ Stent 4-Year AMI Study5

A large, multicenter, real-world study revealed that the XIENCE™ Stent low clinical event rates at 1 year were sustained through 4 years—in both AMI and non-AMI patients.
 

At 1 Year and 4 Years No Significant Difference in AMI and Non-AMI Patients
 

Target lesion failure was not significantly different at 4 years, p<0.09, in AMI vs non-AMI patients.
Definite/probable stent thrombosis was not significantly different at 4 years, p<0.13, in AMI vs non-AMI patients.

EXAMINATION STEMI Data: Low XIENCE™ Stent Acute ST6

XIENCE™ Stent also demonstrates safety among ST-elevation myocardial infarction (STEMI) patients, a subgroup of AMI patients. At 30 days, the rate of definite stent thrombosis (ST) with XIENCE™ Stent vs bare metal stents (BMS) was significantly lower: 0.4% vs 1.6%, p=0.02.

In STEMI patients, the stent thrombosis rate with XIENCE Stent rate is 4 times lower than that of bare metal stents at 30 days.

XIENCE™ Stent STEMI Data at 1 Year6

At 12 months 98% of patients with STEMI are free of target lesion revascularization (TLR).

XIENCE Stent shows 98% Freedom from TLR at 1 Year.

XIENCE™ Stent Long-Term STEMI Data7

The EXAMINATION trial looked at the AMI subgroup of STEMI patients, a subgroup of AMI patients. At both 1 and 5 years XIENCE™ Stents performed better than BMS in an all-comer population.6,7

In STEMI patients, ST and TLR rates are lower with XIENCE Stent vs bare metal stents at both 1 and 5 years.
Event Rates at 1 and 5 Years

“The benefit of EES in ST-elevation myocardial infarction at long term is reassuring and confirms the use of [XIENCE™ Stent] second-generation stents as the current gold standard treatment in this clinical context.”
—Manel Sabaté, et al.7

XIENCE™ Stent Very Long-Term STEMI Data—7 Years8

A meta-analysis examined trials (n=1,581) comparing XIENCE™ Stent second generation DES vs first generation DES—sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). XIENCE™ Stent conferred significantly lower rates of ST and target vessel revascularization (TVR) at 7 years.
 

XIENCE™ Stent vs First-Generation DES in STEMI Patients
 

Stent Thrombosis
7-year data show that, vs first generation DES, XIENCE second generation DES has significantly lower ST and TVR.
Target Vessel Revascularization
7-year data show that, vs first generation DES, XIENCE second generation DES has significantly lower ST and TVR.

Very Low 1-Year Event Rates in STEMI Registry9

One-year clinical outcomes from the XIENCE™ Stent STEMI Registry further revealed that the XIENCE™ Stent was associated with a low incidence of clinical events—including stent thrombosis—even in a high-risk STEMI population.
 

STEMI Registry shows XIENCE Stent with low 1.8% target vessel failure (primary endpoint).
STEMI Registry shows XIENCE Stent with low 2% MACE (cardiac death, MI, target lesion revascularization)
STEMI Registry shows XIENCE Stent with low 0.76% rate of definite ST.
Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Morino Y, et al. Cardiovasc Interv Ther. 2019;34:14-24.
  3. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:Suppl B – TCT-291.
  4. Data on file at Abbott.
  5. Sudhir K, et al. J Am Coll Cardiol. 2014;64(11 Suppl) – TCT-39.
  6. Sabaté M, et al. Lancet. 2012;380:1482-1490.
  7. Sabaté M, et al. Lancet. 2016;387:357-366.
  8. De Luca G, et al. Int J Cardiol. 2017;244:121-127.
  9. Otsuji S, et al. EuroPCR 2019 – XIENCE STEMI Registry.

MAT-2101788 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0